These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48 related articles for article (PubMed ID: 32379358)
21. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease. Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists. Clark-Snustad KD; Singla A; Lee SD Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825 [TBL] [Abstract][Full Text] [Related]
23. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort. Nuti F; Civitelli F; Bloise S; Oliva S; Aloi M; Latorre G; Viola F; Cucchiara S J Crohns Colitis; 2016 Jan; 10(1):5-12. PubMed ID: 26188350 [TBL] [Abstract][Full Text] [Related]
24. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334 [TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease. Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635 [TBL] [Abstract][Full Text] [Related]
26. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. Srinivasan A; van Langenberg DR; Little RD; Sparrow MP; De Cruz P; Ward MG Aliment Pharmacol Ther; 2020 Jun; 51(12):1342-1352. PubMed ID: 32379358 [TBL] [Abstract][Full Text] [Related]
27. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Billioud V; Sandborn WJ; Peyrin-Biroulet L Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178 [TBL] [Abstract][Full Text] [Related]
28. [Anti-TNF therapy in treatment of luminal Crohn's disease]. Marko B; Prka L Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301 [TBL] [Abstract][Full Text] [Related]
29. Dose escalation of biologics in Crohn's disease: critical review of observational studies. Einarson TR; Bereza BG; Ying Lee X; Lelli F Curr Med Res Opin; 2017 Aug; 33(8):1433-1449. PubMed ID: 28537467 [TBL] [Abstract][Full Text] [Related]